A Phase I Study of High-Dose Carfilzomib for Newly Diagnosed Multiple Myeloma

Full Title

Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study

Purpose

Carfilzomib in combination with the drugs lenalidomide and dexamethasone is a treatment for multiple myeloma that persists despite prior therapy. However, carfilzomib is not currently used to treat patients newly diagnosed with multiple myeloma.

In this study, researchers want to assess the safety of high doses of carfilzomib given with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Carfilzomib is given intravenously (by vein), and lenalidomide and dexamethasone are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that is previously untreated or has not been treated with more than one regimen of therapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Neha Korde at 212-639-7664.

Protocol

15-326

Phase

I/II

Investigator

Co-Investigators